Abstract 4984: Association of PTEN and P16 Mutational Status with MITF Expression May Provide a Novel Context for a Phenotype Switch in Melanoma
Bradford R. Brooks,Holly Yin,Donald Chow,Chris Sereduk,Julie Koeman,Chaonan Qian,Jeffrey P. MacKeigan,Sungwon Jung,Seungchan Kim,Mai Xu,Ashani Weeraratna,Kevin M. Brown,Jeffrey Trent
DOI: https://doi.org/10.1158/1538-7445.am2011-4984
IF: 11.2
2011-01-01
Cancer Research
Abstract:Abstract For the last decade, array-based genomic screening has significantly advanced our understanding of genes involved in cancer development and progression. Moreover, genes identified in those screenings have subsequently been the focus of drug development efforts, ultimately leading to clinical trials. However, the efficient translation of cancer genomics results into the development of more effective therapeutics has been limited in part by the need for robust, high-throughput, functional validation of genes and pathways of interest in well-defined model systems. In order to identify new therapeutic targets in melanoma genomes, we have applied high-throughput RNA interference (RNAi) screening to well-characterized melanoma cell lines. We characterized a panel of 65 melanoma cell lines for genome-wide copy number changes and gene expression, as well as the mutation status of known melanoma genes (BRAF, HRAS, NRAS, KRAS, PTEN, CDKN2A, and TP53). From this panel, 18 cell lines were screened against some 1,250 genes (696 kinases, 550 supplemental; 4 siRNAs per gene) to identify modifiers of melanoma cell survival. A striking finding from our data is that MITF expression appears to be a determinant of invasive context and, furthermore, is associated with changes in both p16 and PTEN status. In the cell lines we examined, high MITF expression correlated with wild-type PTEN status, whereas PTEN was deleted or mutated in 30-35% of cell lines having low MITF expression. Similarly, p16 was unaltered in 40-45% of the cell lines that had high MITF expression but remained unaltered in only 20-25% of low MITF-expressing cell lines. The loss of p16 and PTEN are correlated with an aggressive phenotype in melanoma, and we confirmed by Western analysis that in cell lines with high MITF, p16 is present, but in cell lines with low MITF, p16 expression is absent. In agreement with the current literature, no association could be found with BRAF mutational status. Moreover, these data confirm that MITF is associated with the switch in phenotype from a proliferative to an invasive state in melanoma in a BRAF-independent manner, which in turn is associated with an increase in WNT5A expression, a change we previously have suggested is a critical determinant of melanoma metastasis. Results to be presented, aligned with new studies of sequence variants of MITF (Brown et al., unpublished), may help define a novel context for invasive potential of the important disease. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 4984. doi:10.1158/1538-7445.AM2011-4984